Holy Stone Healthcare Co Ltd

Holy Stone Healthcare's capital structure is characterized by a low debt-to-equity ratio of 0.06, indicating a conservative leverage profile. The company holds significant liquidity with cash and equivalents amounting to TWD 144.11 million, which is more than double its total liabilities of TWD 37.68 million, as reflected in a current ratio of 5.29. However, the company reported negative operating cash flow of TWD -109.13 million and free cash flow of TWD -106.17 million, suggesting ongoing cash burn despite its strong liquidity position. Profitability metrics are weak, with a return on equity of -60.9% and a return on assets of -50.49%, both significantly below the industry median for pharmaceuticals. The company reported a net loss of TWD -111.35 million and an operating loss of TWD -145.58 million, indicating a challenging operating environment. These results are inconsistent with the typical performance of firms in the pharmaceuticals industry, which usually benefit from high-margin product lines. Holy Stone Healthcare's revenue is not disclosed in the latest financial snapshot, but the company operates in both domestic and overseas markets. Given the lack of segment-specific revenue data, it is unclear whether the company has significant geographic concentration or diversification. The absence of detailed segment reporting limits the ability to assess exposure to specific regions or product lines. The company's growth trajectory is uncertain, as no revenue history is available in the provided data. The outlook for the current fiscal year is not quantified, and no numeric deltas are provided for the next fiscal year. The negative operating and net income suggest that the company is not currently generating sustainable earnings, which could impact its ability to grow organically or through acquisitions. Risk factors include the company's negative cash flows and operating losses, which could lead to liquidity constraints if the cash burn continues. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative free cash flow and operating cash flow could signal potential future dilution pressure if it needs to raise capital to fund operations. Recent events, including filings and transcripts, are not detailed in the provided data. The company's 10-K Risk Factors language and other disclosures are not available, which limits the ability to assess specific risks related to its operations, such as regulatory changes, product liability, or supply chain disruptions.